Lv11
10 积分 2023-10-12 加入
Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study
4小时前
已完结
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials
5小时前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
24天前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
1个月前
已完结
Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning
1个月前
已完结
Proximity between LAG-3 and the T cell receptor guides suppression of T cell activation and autoimmunity
2个月前
已完结
Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers
2个月前
已完结
CD19-CAR T-cell therapy induces deep tissue depletion of B cells
2个月前
已完结
Anti–CD19 CAR T Cells in Refractory Immune Thrombocytopenia of SLE
2个月前
已完结
Systemic lupus erythematosus-complicating immune thrombocytopenia: From pathogenesis to treatment
2个月前
已完结
皖公网安备34019202002308
